High concentration formulation

Abstract

The present disclosure provides high concentration formulations of cortexolone-17α-propionate suitable for treating alopecia.

What is claimed is: 
     
         1 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max  of cortexolone-17α-propionate of about 2 ng/ml to about 6 ng/ml after topical administration. 
     
     
         2 . The pharmaceutical formulation of  claim 1 , wherein said formulation is administered twice daily. 
     
     
         3 . The pharmaceutical formulation of  claim 1 , wherein the pharmaceutical formulation is a semi-solid formulation. 
     
     
         4 . The pharmaceutical formulation of  claim 3 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment. 
     
     
         5 . The pharmaceutical formulation of  claim 4 , wherein the semi-solid formulation is a cream. 
     
     
         6 . The pharmaceutical formulation of  claim 1 , wherein the pharmaceutical formulation is a liquid. 
     
     
         7 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max  of cortexolone-17α-propionate less than about 3 ng/ml after topical administration. 
     
     
         8 . The pharmaceutical formulation of  claim 7 , wherein said formulation is administered twice daily. 
     
     
         9 . The pharmaceutical formulation of  claim 7 , wherein the pharmaceutical formulation is a semi-solid formulation. 
     
     
         10 . The pharmaceutical formulation of  claim 9 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment. 
     
     
         11 . The pharmaceutical formulation of  claim 10 , wherein the semi-solid formulation is a cream. 
     
     
         12 . The pharmaceutical formulation of  claim 7 , wherein the pharmaceutical formulation is a liquid. 
     
     
         13 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max  of cortexolone-17α-propionate less than about 2 ng/ml after topical administration. 
     
     
         14 . The pharmaceutical formulation of  claim 13 , wherein said formulation is administered twice daily. 
     
     
         15 . The pharmaceutical formulation of  claim 13 , wherein the pharmaceutical formulation is a semi-solid formulation. 
     
     
         16 . The pharmaceutical formulation of  claim 15 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment. 
     
     
         17 . The pharmaceutical formulation of  claim 16 , wherein the semi-solid formulation is a cream. 
     
     
         18 . The pharmaceutical formulation of  claim 13 , wherein the pharmaceutical formulation is a liquid.